Likun Chen

2.8k total citations · 1 hit paper
86 papers, 1.5k citations indexed

About

Likun Chen is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Likun Chen has authored 86 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 56 papers in Oncology, 48 papers in Pulmonary and Respiratory Medicine and 15 papers in Molecular Biology. Recurrent topics in Likun Chen's work include Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (32 papers) and Brain Metastases and Treatment (11 papers). Likun Chen is often cited by papers focused on Lung Cancer Treatments and Mutations (39 papers), Lung Cancer Research Studies (32 papers) and Brain Metastases and Treatment (11 papers). Likun Chen collaborates with scholars based in China, United States and Hong Kong. Likun Chen's co-authors include Xue Hou, Hongyun Zhao, Yan Huang, Yuanyuan Zhao, Li Zhang, Yuxiang Ma, Yunpeng Yang, Ningning Zhou, Wenfeng Fang and Liwu Fu and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Likun Chen

79 papers receiving 1.5k citations

Hit Papers

Camrelizumab (SHR-1210) alone or in combination with gemc... 2018 2026 2020 2023 2018 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials
    2018 326 citations Wenfeng Fang, Yunpeng Yang et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Likun Chen China 21 815 605 484 297 162 86 1.5k
K. Syrigos Greece 23 1.1k 1.4× 638 1.1× 388 0.8× 288 1.0× 246 1.5× 73 1.9k
Xiuyu Cai China 24 1.0k 1.3× 659 1.1× 438 0.9× 321 1.1× 282 1.7× 99 2.1k
Wanqing 10 543 0.7× 335 0.6× 590 1.2× 429 1.4× 305 1.9× 18 1.5k
Xue Hou China 26 1.3k 1.6× 1.0k 1.7× 376 0.8× 317 1.1× 387 2.4× 104 2.1k
Elena Verri Italy 17 711 0.9× 551 0.9× 324 0.7× 407 1.4× 156 1.0× 55 1.2k
Rongshou 9 489 0.6× 298 0.5× 496 1.0× 368 1.2× 274 1.7× 14 1.3k
Siwei 10 490 0.6× 298 0.5× 502 1.0× 368 1.2× 276 1.7× 21 1.3k
Nerina Denaro Italy 19 558 0.7× 455 0.8× 385 0.8× 283 1.0× 307 1.9× 93 1.4k
Jean‐Baptiste Guy France 19 440 0.5× 458 0.8× 391 0.8× 209 0.7× 149 0.9× 90 1.4k
Thomas Makatsoris Greece 22 1.0k 1.2× 338 0.6× 362 0.7× 198 0.7× 147 0.9× 85 1.5k

Countries citing papers authored by Likun Chen

Since Specialization
Citations

This map shows the geographic impact of Likun Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Likun Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Likun Chen more than expected).

Fields of papers citing papers by Likun Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Likun Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Likun Chen. The network helps show where Likun Chen may publish in the future.

Co-authorship network of co-authors of Likun Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Likun Chen. A scholar is included among the top collaborators of Likun Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Likun Chen. Likun Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
4.
Zhou, Jiawang, Jiexin Li, Zhaotong Wang, et al.. (2023). N6 -Methyladenosine Promotes Translation of VEGFA to Accelerate Angiogenesis in Lung Cancer. Cancer Research. 83(13). 2208–2225. 42 indexed citations
5.
Yu, Hui, Jingyu Chen, Yixin Zhou, et al.. (2023). Impact of prophylactic dexamethasone on the efficacy of immune checkpoint inhibitors plus platinum-based chemotherapy in patients with advanced Non-Squamous Non-Small-Cell lung cancer. International Immunopharmacology. 125(Pt B). 111138–111138. 7 indexed citations
6.
7.
Fang, Wenfeng, Jianwen Li, Delan Li, et al.. (2021). Impact of STAT1 polymorphisms on crizotinib-induced hepatotoxicity in ALK-positive non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology. 147(3). 725–737. 12 indexed citations
8.
Lin, Xinqing, Haiyi Deng, Likun Chen, et al.. (2021). Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience. Translational Lung Cancer Research. 10(1). 415–429. 12 indexed citations
9.
Liu, Xuewen, Yuming Rong, Ning Lyu, et al.. (2020). MET exon 14 skipping mutation, amplification and overexpression in pulmonary sarcomatoid carcinoma: A multi-center study. Translational Oncology. 13(12). 100868–100868. 16 indexed citations
10.
Liu, Xuewen, Fang Wang, C. Xu, et al.. (2020). Genomic origin and intratumor heterogeneity revealed by sequencing on carcinomatous and sarcomatous components of pulmonary sarcomatoid carcinoma. Oncogene. 40(4). 821–832. 18 indexed citations
11.
Zhao, Jun, Gen Lin, Minglei Zhuo, et al.. (2019). Next-generation sequencing based mutation profiling reveals heterogeneity of clinical response and resistance to osimertinib. Lung Cancer. 141. 114–118. 30 indexed citations
12.
Fang, Wenfeng, Yunpeng Yang, Yuxiang Ma, et al.. (2018). Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. The Lancet Oncology. 19(10). 1338–1350. 326 indexed citations breakdown →
13.
Chen, Xinru, Yu Zhang, Jiabin Lu, et al.. (2017). Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical-Pathologic Characteristics, and Response to ALK Inhibitor. Translational Oncology. 10(2). 115–120. 22 indexed citations
14.
Chen, Zhen, Yifan Chen, Meng Xu, et al.. (2016). Osimertinib (AZD9291) Enhanced the Efficacy of Chemotherapeutic Agents in ABCB1- and ABCG2-Overexpressing Cells In Vitro, In Vivo , and Ex Vivo. Molecular Cancer Therapeutics. 15(8). 1845–1858. 45 indexed citations
15.
Hu, Zhihuang, Wenhua Liang, Yunpeng Yang, et al.. (2016). Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting. Medicine. 95(2). e2476–e2476. 18 indexed citations
16.
Qin, Tao, Ningning Zhou, Xiao-Xiao Dinglin, et al.. (2016). Benefit from thoracic radiotherapy in patients with extensive-disease small-cell lung cancer with elevated lactate dehydrogenase. OncoTargets and Therapy. 9. 1095–1095. 6 indexed citations
17.
Chen, Likun. (2013). Applying "paradigm contending" to tourism research: taking "authenticity" tourism research as an example.. Luyou xuekan. 28(1). 30–38.
18.
He, Xuexin, He Huang, Likun Chen, et al.. (2011). A pharmacokinetic and safety study of single dose intravenous combretastatin A4 phosphate in Chinese patients with refractory solid tumours. British Journal of Clinical Pharmacology. 71(6). 860–870. 29 indexed citations
19.
Wang, Feng‐Hua, Yang Zhang, Hongyun Zhao, et al.. (2010). Validation of a clinical prognostic model in Chinese patients with metastatic and advanced pretreated non-small cell lung cancer treated with gefitinib. Medical Oncology. 28(1). 331–335. 4 indexed citations
20.
Chen, Likun, et al.. (2009). Brain Radiotherapy Combined with Sequential Chemotherapy in Non-Small-Cell Lung Cancer Patients with Brain Metastases. SHILAP Revista de lepidopterología. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K. Syrigos Breakdown of academic impact, for papers by Xiuyu Cai Breakdown of academic impact, for papers by Wanqing Breakdown of academic impact, for papers by Xue Hou Breakdown of academic impact, for papers by Elena Verri Breakdown of academic impact, for papers by Rongshou Breakdown of academic impact, for papers by Siwei Breakdown of academic impact, for papers by Nerina Denaro Breakdown of academic impact, for papers by Jean‐Baptiste Guy Breakdown of academic impact, for papers by Thomas Makatsoris
Rankless by CCL
2026